Replies to post #141438 on Biotech Values

[acgood]

Ono paid nearly $60m for Japanese rights to carfilzomib after p2 data, ARQL got $30m Asian deal after phase 1...I'm sure there are others.

[DewDiligence]

an example of high up-front for Asia-only deal?

VRTX got $33M up-front from Mitsubishi in 2004 for the Asian rights to Telaprevir when it was just entering phase-1 (http://investors.vrtx.com/releasedetail.cfm?releaseid=233090 ).

Five years later, when Telaprevir was well on its way, VRTX monetized the milestones and royalties from the Mitsubishi deal for a lump sum of $105M plus $15-65M in contingencies (#msg-40126798).

[acgood]

two notes re crizotinib+ganetespib trial

-These trials are not company sponsored. Combo trial is initiating now at MSKCC
-The single agent ALK+ trial will include ex-US sites in Europe, Asia where crizotinib not yet approved, whihc should have more robust enrollment demand.